National Cancer Institute Thesaurus

Last uploaded: March 25, 2019
Preferred Name

Blinatumomab

Synonyms

Blincyto

BLINATUMOMAB

Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody

MT-103

Blinatumomab

Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103

MEDI-538

Definitions

A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.

ID

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C62528

Accepted_Therapeutic_Use_For

relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)

CAS_Registry

853426-35-4

code

C62528

Concept_In_Subset

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157712

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C157711

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C63923

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C128784

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978

Contributing_Source

CTRP

FDA

DEFINITION

A recombinant, single-chain, anti-CD19/anti-CD3 bispecific monoclonal antibody with potential immunostimulating and antineoplastic activities. Blinatumomab possesses two antigen-recognition sites, one for the CD3 complex, a group of T cell surface glycoproteins that complex with the T cell receptor (TCR), and one for CD19, a tumor-associated antigen (TAA) overexpressed on the surface of B cells. This bispecific monoclonal antibody brings CD19-expressing tumor B-cells and cytotoxic T lymphocytes (CTLs) and helper T lymphocytes (HTLs) together, which may result in the CTL- and HTL-mediated cell death of CD19-expressing B-lymphocytes.

Display_Name

Blinatumomab

FDA_UNII_Code

4FR53SIF3A

FULL_SYN

Blincyto

BLINATUMOMAB

Anti-CD19 x Anti-CD3 Bispecific Monoclonal Antibody

MT-103

Blinatumomab

Anti-CD19/Anti-CD3 Recombinant Bispecific Monoclonal Antibody MT103

MEDI-538

label

Blinatumomab

Legacy_Concept_Name

Anti-CD19_Anti-CD3_Bispecific_Monoclonal_Antibody

PDQ_Closed_Trial_Search_ID

487684

PDQ_Open_Trial_Search_ID

487684

Preferred_Name

Blinatumomab

prefixIRI

ncit:C62528

Semantic_Type

Immunologic Factor

Amino Acid, Peptide, or Protein

UMLS_CUI

C3853839

subClassOf

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112883

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C129822

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C112889

http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C1454

Delete Subject Author Type Created
No notes to display
Create New Mapping

Delete Mapping To Ontology Source
http://purl.bioontology.org/ontology/UATC/L01XC19 ATC LOOM
http://purl.bioontology.org/ontology/NDFRT/N0000191284 NDFRT LOOM
http://purl.bioontology.org/ontology/NDDF/015799 NDDF LOOM
http://purl.obolibrary.org/obo/DRON_00730842 DRON LOOM
http://phenomebrowser.net/ontologies/mesh/mesh.owl#C510808 RH-MESH LOOM
http://purl.bioontology.org/ontology/SNOMEDCT/716122004 SNOMEDCT LOOM
http://purl.bioontology.org/ontology/RXNORM/1597258 RXNORM LOOM
http://purl.bioontology.org/ontology/MESH/C510808 MESH LOOM
http://purl.bioontology.org/ontology/VANDF/4033958 VANDF LOOM